Optimus Pharma

What Optimus Pharma does

Optimus Pharma is a Hyderabad-headquartered Contract Development and Manufacturing Organization (CDMO) that delivers integrated, end-to-end services for small molecule drug substances and drug products, operating across four manufacturing units located in Hyderabad and Visakhapatnam (Andhra Pradesh). The platform spans drug substance intermediates, small molecule APIs (including NCE/NDA, custom, and generic), drug product intermediates (pellets, micronized APIs, spray-dried materials), and finished dosage formulations (oral solids, semi-solids, immediate and controlled release). The company serves global pharmaceutical and biotechnology clients — including Pfizer, Teva, Sandoz, Sun Pharma, Cipla, Dr. Reddy's, Aurobindo, Mylan, Biocon, Torrent, Hikma, and Celltrion — across more than 40 countries.

Its technical differentiation rests on a 150+ scientist R&D team at a CSIR-approved center, expertise in complex chemistry (chiral synthesis, Birch, Grignard, Suzuki, Mitsunobu, Wolff-Kishner reductions, and others), and specialty manufacturing capabilities including cGMP-compliant spray drying for amorphous solid dispersions, advanced jet-milled micronization, multi-particulate pellet systems, and nitrosamine / NDSRI impurity detection using XRD, HPLC, LC-MS, and GC-MS. Manufacturing infrastructure totals 822 KL of reactor capacity across the three API/intermediate units, plus a USFDA-inspected Unit 4 FDF facility with annual capacity of 1.6 billion tablets, 400 million capsules, 40+ MT of pellets, and 30+ million tubes.

The business model is B2B contract services revenue combined with API and FDF product sales. Pricing is quote-based and tied to project scope, volume, and complexity. Go-to-market relies on dedicated enterprise field sales, direct client engagement, and a heavy trade-show calendar (DCAT Week, CPHI Worldwide / North America, ChemSpec Europe, Pharmaconex). Ownership sits with Sekhmet Pharmaventures Pvt. Ltd. — part of the Singapore-based Gamot API Pte Ltd. investment platform formed by PAG, CX Partners, and Samara Capital, which acquired a majority stake in May 2022 to consolidate a multi-vertical Indian pharma platform spanning intermediates, API, FDF, and CDMO services. The group operates through three affiliated India-domiciled private limited entities: Optimus Drugs Private Limited, Optimus Pharma Private Limited, and Optimus Life Science Private Limited.

Name

Optimus Pharma

Legal name

Optimus Drugs Private Limited

Website

https://optimuspharma.com/

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Optimus Pharma is a Hyderabad-based CDMO delivering integrated contract development and manufacturing of small molecule drug substances and drug products, serving global pharmaceutical and biotech companies across 40+ countries with USFDA-inspected multi-unit facilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract drug manufacturing
• Active pharmaceutical ingredients
• Finished dosage formulations
• Pharmaceutical contract services
• Custom API synthesis

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. CDMO/CMO Services: Contract development and manufacturing services for drug substances and drug products. Revenue generated through development fees, manufacturing fees, and tech transfer services for pharmaceutical companies across the product lifecycle from clinical to commercial scale.
2. API Manufacturing: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and intermediates to pharmaceutical companies globally.
3. Finished Dosage Formulation Manufacturing: Manufacturing of oral solids and semi-solids including tablets, capsules, creams, and ointments for commercial markets.
4. R&D Services: Research and development services including analytical method development, validation, process optimization, and regulatory support.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Optimus Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end integrated solutions from clinical development to commercial manufacturing of small molecule drug substances (APIs and advanced intermediates) and drug products. The company delivers custom synthesis, process scale-up, cGMP-compliant API manufacturing, formulation development, spray drying, micronization, multi-particulate pellet systems, and finished dosage formulation for global pharmaceutical innovators and generics manufacturers.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Substance Intermediates (CDMO) End-to-end CDMO support from clinical to commercial scale through custom synthesis, process scale-up, and cGMP/non-GMP manufacturing of advanced intermediates for global pharmaceutical clients.
• Drug Substance (API) CDMO Specialized small-molecule API development and manufacturing offering services across NCE/NDA development, custom APIs, and generic APIs for global pharma and biotech clients.
• Drug Product Intermediates Supply of drug product intermediates including pellets, micronized APIs, and spray-dried materials to support a range of formulation requirements for pharmaceutical customers.
• Drug Product (Finished Dosage Formulation) CDMO Development and manufacturing of oral solids, semi-solids, immediate-release, and controlled-release drug product formulations, including seamless technology transfers for existing client projects.
• Value Added Services Supporting CDMO offerings including analytical method development and validation, process optimization, regulatory and CMC services, and dedicated technology transfer services for client projects.
• API Product List Catalog of active pharmaceutical ingredients (APIs) manufactured by Optimus Pharma including generic and custom APIs supplied to pharmaceutical companies globally.
• FDF Products (Finished Dosage Formulations) Catalog of finished dosage formulations including tablets, capsules, pellets, and semi-solid forms manufactured at the USFDA-inspected Unit 4 FDF facility for commercial markets.
• Intermediates Catalog of advanced intermediates supplied for use in API manufacturing by pharmaceutical clients globally.

Quantifiable outcome

• Serving clients across 40+ countries globally
• +2 more outcomes

Named customers18 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Divis Laboratories: One of India's largest API and intermediates manufacturers with growing CDMO services for global pharma. Directly comparable to Optimus in small molecule API/intermediate manufacturing, regulatory accreditations and global customer mix.
• Laurus Labs: Indian-headquartered API and CDMO business serving global generic and innovator pharma customers. Highly comparable to Optimus in API/intermediate manufacturing, FDF capabilities and end-to-end CDMO positioning.
• Piramal Pharma Solutions: Global CDMO offering integrated drug substance and drug product services across multiple sites, including India. Direct competitor to Optimus in offering end-to-end small molecule development and manufacturing to innovator and generic customers.
• Syngene International: India-based CRO/CDMO providing development and manufacturing services to global pharma. Comparable to Optimus in serving innovator biotech customers, though Syngene has a stronger discovery/CRO tilt.
• Neuland Laboratories: Indian CDMO focused on small molecule APIs, intermediates and custom manufacturing for global pharma. Highly comparable scale and scope to Optimus's API/CDMO operations.
• Suven Pharmaceuticals: India-based CDMO providing API, intermediate and formulation development services to global pharma. Closely comparable to Optimus in service mix, scale and customer profile.
• Sai Life Sciences: Indian CRO-CDMO offering small molecule drug substance and drug product services. Overlaps with Optimus in serving innovator pharma customers and providing integrated development and manufacturing.
• Jubilant Pharmova (CDMO business): Indian pharma company with a sizable CDMO segment offering APIs, intermediates and sterile injectables manufacturing. Comparable to Optimus in API/intermediate capabilities and global customer mix.
• MSN Laboratories: Indian-headquartered API and finished dosage manufacturer with growing CDMO focus. Comparable to Optimus in integrated small molecule manufacturing and USFDA-inspected facilities.

Broad incumbents

• Aurobindo Pharma: Large Indian generic pharmaceutical company with significant API manufacturing and a growing CDMO offering. Overlaps with Optimus in API/intermediate supply and finished dosage manufacturing, but Aurobindo operates on a much larger scale and broader product portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CommsSekhmet
• YouTubeyoutube.com/@sekhmetpharmaventures
• LinkedInlinkedin.com/company/optimus-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optimus Pharma